CARAT - Chimeric Antigen Receptors (CARs) for Advanced Therapies
an EU-funded collaborative research project involving 8 partners from 4 different European countries (France, Germany, Italy & United Kingdom).
- CARAT's goal
is to develop an efficient and safe technology platform for advanced cellular therapies, namely to manufacture CAR T-cell products for personalized treatment of cancer patients.
- Recent Success Stories
of CAR-based therapies have raised enormous expectations to cure severely ill patients: CARs were introduced into cells of the immune system, typically T-cells, by genetic engineering.
- Initial clinical studies
demonstrated considerable evidence that these artificial recognition molecules allow specific targeting of immune responses towards complete and stable eradication of cancer cells.
- Translation into the clinic
of such advanced therapeutic concepts is extremely difficult as the manufacture of CAR-modified T-cells is technologically complex and expensive.
- The CARAT technology platform
will thus enable the automated, safe, and cost efficient manufacture of more effective CAR-modified T-cells. Thereby, CARAT will spread the clinical use of CAR T-cell technologies with the ultimate goal of serving patients with so far incurable hematologic malignancies and solid tumours like colon, pancreas or lung cancer – everywhere in Europe.
The CARAT consortium comprises a multi-national team of leading experts from eight European partnering institutions.
Recent success stories of cancer therapy with CAR-modified T-cells have raised enormous scientific and public expectations to cure severely ill patients.
9th Institut Cochin Symposium in Paris, France organised by CARAT partner INSERM
Horizon - The EU Research & Innovation Magazine has published an article on the advances of cell production factories in bringing life-saving...
26/09/2018– 28/09/2018, Freiburg, Germany
16/10/2018– 19/10/2018, Lausanne, Switzerland
16/11/2018, Paris, France
Human Gene Therapy, Volume: 28 Issue 10: October 1, 2017
Human Gene Therapy, Volume 28, pp 1105-1115; doi:10.1089/hum.2017.149